Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy

[1]  David A. Williams,et al.  Lentiviral gene therapy for X-linked chronic granulomatous disease , 2020, Nature Medicine.

[2]  A. Gennery,et al.  Two decades of excellent transplant survival for chronic granulomatous disease: a supraregional immunology transplant center report. , 2019, Blood.

[3]  F. Bushman,et al.  Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges , 2019, Nature Reviews Drug Discovery.

[4]  J. Puck,et al.  Lentiviral Gene Therapy Combined with Low‐Dose Busulfan in Infants with SCID‐X1 , 2019, The New England journal of medicine.

[5]  L. Biasco,et al.  Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study , 2019, The Lancet. Haematology.

[6]  B. Zweiman,et al.  Neutrophils , 2019, Nursing Critical Care.

[7]  A. Schambach,et al.  Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease. , 2018, Human gene therapy. Clinical development.

[8]  N. Rider,et al.  Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease , 2018, Journal of the Pediatric Infectious Diseases Society.

[9]  L. Milanesi,et al.  VISPA2: a scalable pipeline for high-throughput identification and annotation of vector integration sites , 2017, BMC Bioinformatics.

[10]  Barbara Engel,et al.  Clinical efficacy of gene-modified stem cells in adenosine deaminase–deficient immunodeficiency , 2017, The Journal of clinical investigation.

[11]  C. Brombin,et al.  Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  P. Rancoita,et al.  Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial , 2016, The Lancet.

[13]  A. Schulz,et al.  Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. , 2016, Blood.

[14]  J. Puck,et al.  Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2016, Blood.

[15]  M. Essers,et al.  Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions. , 2016, The Journal of allergy and clinical immunology.

[16]  J. Tchinda,et al.  Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing. , 2015, Current gene therapy.

[17]  D. Trono,et al.  Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Frederic D Bushman,et al.  Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. , 2015, JAMA.

[19]  S. Holland,et al.  Common severe infections in chronic granulomatous disease. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Yosvany López,et al.  Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites , 2014, Genome Medicine.

[21]  A. Fischer,et al.  Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study , 2014, The Lancet.

[22]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[23]  Luca Biasco,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.

[24]  J. Casanova,et al.  Pulmonary manifestations of chronic granulomatous disease , 2013, Expert review of clinical immunology.

[25]  Anat Melamed,et al.  Estimating abundances of retroviral insertion sites from DNA fragment length data , 2012, Bioinform..

[26]  E. Laurenti,et al.  Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease , 2011, Gene Therapy.

[27]  Gianluigi Zanetti,et al.  Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. , 2011, Blood.

[28]  F. Bushman,et al.  The host genomic environment of the provirus determines the abundance of HTLV-1–infected T-cell clones , 2011, Blood.

[29]  Cory Y. McLean,et al.  GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.

[30]  Hans Martin,et al.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.

[31]  D. Kuhns,et al.  Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. , 2010, Blood.

[32]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[33]  A. Schambach,et al.  Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Abdul Hakkim,et al.  Restoration of NET formation by gene therapy in CGD controls aspergillosis. , 2009, Blood.

[35]  C. von Kalle,et al.  Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Hanno Glimm,et al.  High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.

[37]  A. Ballabio,et al.  Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. , 2007, Human gene therapy.

[38]  Paul Shinn,et al.  HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  J. Ward.  Lymphomas and leukemias in mice. , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[40]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[41]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[42]  N. Copeland,et al.  Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. , 2005, Blood.

[43]  M. Dinauer,et al.  Gene Therapy for Chronic Granulomatous Disease , 2003, Acta Haematologica.

[44]  L. Ailles,et al.  Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences , 2000, Nature Genetics.

[45]  G A Boorman,et al.  Leukemia and Lymphoma Incidence in Rodents Exposed to Low-Frequency Magnetic Fields , 2000, Radiation research.

[46]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[47]  S. Holland,et al.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Cowland,et al.  Granules of the human neutrophilic polymorphonuclear leukocyte. , 1997, Blood.

[49]  H. Ischiropoulos,et al.  Peroxynitrite-mediated oxidation of dihydrorhodamine 123. , 1994, Free radical biology & medicine.

[50]  A. Jesaitis,et al.  Ultrastructural localization of cytochrome b in the membranes of resting and phagocytosing human granulocytes. , 1990, The Journal of clinical investigation.

[51]  R. Clark,et al.  Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation , 1983, The Journal of cell biology.

[52]  K. Rao,et al.  The effect of age, fractionation, and dose on radiation carcinogenesis in various tissues of mice. , 1971, Cancer research.

[53]  Kathryn L. Parsley,et al.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.